Search Results
Results found for "Glaxo Inc"
- Misread the Curve, Misjudge the Drug: Rethinking Antagonism in GPCR Pharmacology
Each subscription includes: Weekly deep dives from Dr.
- Why Intracellular Drugs May Hold the Key to GPCR Therapeutics
residence time—not potency—predicts therapeutic coverage ✅ Insight into cryptic intracellular GPCR sites, including And intracellular targets, including allosteric sites unreachable from the extracellular side, become
- Your GPCR Program Decisions Depend on Good Data Interpretation
Ingo Hartung : State-of-the-art design of small molecule drugs, including PROTACs Dr. FAQ: What’s Included, Who It’s For, Why Now What’s included?
- GPCR Allostery: Unlock Hidden Mechanisms and Make Smarter Drug Decisions
GPCR Premium 🔹 What’s included?
- How Understanding Intracellular Drug Access Can Transform Your GPCR Drug Discovery Program
GPCR Premium What’s included?
- Why Kinetics Matter More Than Kd in GPCR Drug Discovery
alerts, job opportunities, and insider commentary—all designed to help you move faster and smarter in an increasingly GPCR Premium gives you an edge in a fast-moving field. 🔹 Premium Membership FAQ 🔹 What’s included?
- Lab Leadership Without Ego: How Sokhom Pin Built the Happiest Team at Alkermes
He was tasked with building an in vitro pharmacology group from scratch , including infrastructure, hiring
- Unlock the Hidden Complexity Behind GPCRs—From Terry Kenakin’s Vault
studying GPCRs—arguably the most important drug targets in pharmacology—has been wrong… or at least, incomplete
- Signals in Motion: Pain, Metabolism & Terry’s Corner
Meanwhile, incretin and amylin-based therapies are reshaping the obesity drug landscape.
- Pharmacology Isn't What You Think—It's So Much More
Whether you're heading into your first assay or trying to make sense of inconsistent data, Terry gives
- Dr. GPCR and Celtarys Research Join Forces to Expand Access to Innovative GPCR Tools
GPCR partner, Celtarys will be featured across multiple touchpoints in the ecosystem, including the Dr
- Knowing When to Walk, Knowing When to Run: Lessons from the Bench
A tenfold increase in methadone efficacy using PAMs.
- Science Needs Rigor, But Also Joy
But every day also includes squirrel-themed trivia and impromptu debates about obscure molecules.
- Ben Clements on Rescuing Opioids with GPCR Modulators
Redefining Opioid Pharmacology Ben and his colleagues discovered that PAMs can dramatically increase In fact, one of their recent neuroma pain studies showed a tenfold increase in methadone potency. That’s not an incremental advance; that’s a potential paradigm shift. Using PAMs, his team aims to re-sensitize these conditions to opioids without increasing toxicity.
- Mapping Motion: Intermediate States, Deorphanization & Discovery
This course is included with your Premium membership. Access the Course Dr. These on-demand sessions are included with your Premium membership.
- The Perils and Guardrails of Modifying Signalling Proteins in Bioassays
conformational dynamics of the receptor rather than a lowered sensitivity for detecting weaker interactions, as increasing A standard format of GPCR biosensors incorporates a luminescent tag on the G protein Gα subunit and Gβγ Similar effects of varying intensity were observed for several other GPCRs, including the β2-adrenergic Additionally, as mini-G proteins are increasingly implemented in structural determinations of GPCRs and
- 🎄 Have Yourself a Merry Little GPCRmas! ❄ Dec 9 - 15, 2024
GPCR Team This Week’s Highlights: Congratulations to Andrew Tobin for an incredible week filled with prestigious events, including receiving the British Pharmacological Society Vane Medal and switching
- GPCR News Flash! Top Updates You Can't-Miss! + University CheatSheet is finally available! ❄ Dec 2 - 8, 2024
As a Premium Member, you gain exclusive access to this incredible treasure trove we've amassed over the Daridorexant in South Korea Septerna Touches New High, To Report SEP-786 Data In Mid-2025 How GPCR agonists, including
- Reflections on My PhD Journey: Lessons Learned
Procrastination may seem tempting, but tackling your work incrementally will save time and reduce stress
- ⛵Sailing the GPCR Seas: Your Weekly Research Voyage! ⦿ Nov 11 - 17, 2024
exceptional services to achieve our goal of leading a vibrant and healthy life , all thanks to the incredible Embrace the excitement of supporting us and unlocking incredible perks such as: Dr.
- What's Going On with GPCRs?! Find Out in This Week's Update! ⦿ Nov 4 - 10, 2024
This strategic decision to limit free content is essential as we need to increase revenue to support
- Harnessing Deep Mutational Scanning for Enhanced Drug Discovery
natural environment or post-translational modifications observed in humans, potentially leading to inconsistencies Moreover, DMS requires considerable resources, including time, financial investment, and specialised Another promising development is the application of DMS to a wider array of biological systems, including
- Class B1 GPCR Dimerization: Unveiling Its Role in Receptor Function and Signaling
possibility of dimerization in class A and class B GPCRs, however, has been more controversial, despite increasing Class B1 GPCRs are an important subclass of GPCRs that include 15 receptors involved in regulating body Examples of class B1 GPCRs forming homodimers include the secretin receptor (SecR)[6] and GLP-1R [7], SecR dimerization enhances the receptor’s signaling efficiency by increasing its dynamics in a G protein-dependent
- Profiling Immune Cell and Platelet Transcriptomes
Additionally, the study identified unique expression patterns of GPCRs in different immune cell types, including manner also opens doors for exploring the roles of these receptors in various pathological states, including
- Discover the Hottest GPCR News of the Week: Oct 7-13, 2024!
Allow registrants to appreciate the incredible versatility of GPCRs and how small molecules can affect
- GPCR Weekly Whirlwind: Top Receptor Highlights from Sep 30 - Oct 6, 2024!
This Week’s Highlights: Congrats to: Our contributor, Cam Sinh Lu , who has just released an incredible
- Targeted Drug Design through GPCR Mutagenesis: Insights from β2AR
inhibit receptor activity without directly competing with ligands, potentially reducing side effects and increasing GPCRs, including β2AR, play key roles in various conditions, such as asthma, cardiovascular diseases,
- AlphaFold’s Breakthrough in GPCR Research: Revolutionizing Discovery, Yet Awaiting Experimental Proof
AlphaFold3, the latest version, has improved on this by modeling interactions with various compounds, including
- Biased Agonism at the GLP-1 Receptor: A Pathway to Improved Therapeutic Outcomes
our understanding of the molecular basis of biased agonism continues to grow, it is likely to play an increasingly Indeed, incretin-based drugs like Novo Nordisk's Wegovy and Eli Lilly's Zepbound are advancing diabetes Anson, M., et al., Incidence of new onset type 2 diabetes in adults living with obesity treated with
- Unlock the Future of GPCR Science: Breakthroughs and Courses Await | Sep 2 - Sep 8, 2024
, MA 📅 October 2 -3, 2024 Join top researchers to explore the latest in GPCR-targeted drug design, including

























